Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sangamo Therapeutics Inc (NASDAQ:SGMO)

4.10
Delayed Data
As of Jan 17
 -0.30 / -6.82%
Today’s Change
2.65
Today|||52-Week Range
7.60
+34.43%
Year-to-Date
Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates
Jan 17 / Benzinga - Paid Partner Content
Biotech Premarket Movers: IPXL, SGMO, ARLZ
Jan 11 / TheStreet.com - Paid Partner Content
Biotech Premarket Movers: SGMO, IPXL, PTLA
Jan 13 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close4.40
Today’s open4.40
Day’s range4.05 - 4.40
Volume1,166,004
Average volume (3 months)960,399
Market cap$310.7M
Dividend yield--
Data as of 4:00pm ET, 01/17/2017

Growth & Valuation

Earnings growth (last year)-48.72%
Earnings growth (this year)-95.98%
Earnings growth (next 5 years)+24.50%
Revenue growth (last year)-13.80%
P/E ratioNM
Price/Sales16.11
Price/Book1.61

Competitors

 Today’s
change
Today’s
% change
VYGRVoyager Therapeutics...-0.34-2.85%
ADAPAdaptimmune Therapeu...-0.10-2.21%
XBITXBiotech Inc+0.31+3.09%
PTGXProtagonist Therapeu...-0.57-2.92%
Data as of 4:00pm ET, 01/17/2017

Financials

Next reporting dateFebruary 8, 2017
EPS forecast (this quarter)-$0.26
Annual revenue (last year)$39.5M
Annual profit (last year)-$40.7M
Net profit margin-102.94%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Alexander Macrae
Chief Financial Officer &
Executive Vice President
Henry Ward Wolff
Corporate headquarters
Richmond, California

Forecasts


Search for Jobs